United Therapeutics Corporation

United Therapeutics Corporationverified

UTHR

Price:

$272.88

Market Cap:

$12.11B

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unit...[Read more]

Industry

Biotechnology

IPO Date

1999-06-17

Stock Exchange

NASDAQ

Ticker

UTHR

The PE Ratio as of May 2024 (TTM) for United Therapeutics Corporation (UTHR) is 12.92

According to United Therapeutics Corporation’s latest financial reports and current stock price. The company's current PE Ratio is 12.92. This represents a change of 27.51% compared to the average of 10.13 of the last 4 quarters.

United Therapeutics Corporation (UTHR) Historical PE Ratio (quarterly & annually)

How has UTHR PE Ratio performed in the past?

The mean historical PE Ratio of United Therapeutics Corporation over the last ten years is 8.62. The current 12.92 PE Ratio has changed 14.89% with respect to the historical average. Over the past ten years (40 quarters), UTHR's PE Ratio was at its highest in in the December 2017 quarter at 84.10. The PE Ratio was at its lowest in in the March 2015 quarter at -119.45.

Quarterly (TTM)
Annual

Average

8.62

Median

12.04

Minimum

-36.92

Maximum

20.39

United Therapeutics Corporation (UTHR) PE Ratio by Quarter and Year

Discovering the peaks and valleys of United Therapeutics Corporation PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 76.97%

Maximum Annual PE Ratio = 20.39

Minimum Annual Increase = -559.18%

Minimum Annual PE Ratio = -36.92

Quarterly (TTM)
Annual
YearPE RatioChange
202310.45-39.94%
202217.40-14.68%
202120.3956.46%
202013.03-135.30%
2019-36.92-559.18%
20188.04-48.39%
201715.5876.97%
20168.80-20.38%
201511.06-39.73%
201418.34-43.45%

United Therapeutics Corporation (UTHR) Average PE Ratio

How has UTHR PE Ratio performed in the past?

The current PE Ratio of United Therapeutics Corporation (UTHR) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

16.08

5-year avg

4.87

10-year avg

8.62

United Therapeutics Corporation (UTHR) PE Ratio vs. Peers

How is UTHR’s PE Ratio compared to its peers?

United Therapeutics Corporation’s PE Ratio is less than Incyte Corporation (17.26), greater than Alnylam Pharmaceuticals, Inc. (-56.13), greater than Ultragenyx Pharmaceutical Inc. (-5.54), greater than Apellis Pharmaceuticals, Inc. (-11.97), greater than Replimune Group, Inc. (-1.49), greater than Nuvalent, Inc. (-29.96), greater than Ventyx Biosciences, Inc. (-1.40), greater than Ascendis Pharma A/S (-13.63), less than MannKind Corporation (152.27), greater than Larimar Therapeutics, Inc. (-8.41), greater than Day One Biopharmaceuticals, Inc. (-5.71), less than Kiniksa Pharmaceuticals, Ltd. (155.56), greater than BeiGene, Ltd. (-26.39), greater than Akero Therapeutics, Inc. (-6.06), greater than Blueprint Medicines Corporation (-21.96), greater than Vaxcyte, Inc. (-17.58), greater than Legend Biotech Corporation (-16.18),

Build a custom stock screener for United Therapeutics Corporation (UTHR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like United Therapeutics Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

United Therapeutics Corporation (UTHR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like United Therapeutics Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is United Therapeutics Corporation's PE Ratio?

How is the PE Ratio calculated for United Therapeutics Corporation (UTHR)?

What is the highest PE Ratio for United Therapeutics Corporation (UTHR)?

What is the 3-year average PE Ratio for United Therapeutics Corporation (UTHR)?

What is the 5-year average PE Ratio for United Therapeutics Corporation (UTHR)?

How does the current PE Ratio for United Therapeutics Corporation (UTHR) compare to its historical average?